Glioblastoma Therapy
Glioblastoma Therapy - Related Videos
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
0 Views •
Cited by 15 •
2014
A novel methodology that is employed for the treatment of recurrent glioblastomas is described. This treatment approach employs the application of alternating electric tumor treating fields (TTFields), known as TTF Therapy in combination with bevacizumab, a targeted agent that is currently FDA approved as monotherapy.
08:00
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
0 Views •
Cited by 12 •
2019
Glioblastoma is the most common and aggressive primary brain malignancy in adults, with most tumors recurring after initial treatment. Tumor Treating Fields (TTFields) therapy is the newest treatment modality for glioblastoma. Here, we describe the proper application of TTFields-transducer arrays on patients and discuss theory and aspects of treatment.
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
0 Views •
Cited by 17 •
2015
The lymphodepletive and immunomodulatory effects of chemotherapy and radiation standard of care can be leveraged to enhance the antitumor efficacy of T cell immunotherapy. We outline a method for generating EGFRvIII-specific chimeric antigen receptor (CAR) T cells and administering them in the context of glioblastoma standard of care.
03:47
Implantation of a Flexible Biocompatible Probe in a Glioblastoma Mouse Model
0 Views •
2025
Source: Lefevre, M. C., et al., Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma. J. Vis. Exp. (2022)This video demonstrates the implantation of a flexible, biocompatible probe in a glioblastoma mouse model to deliver targeted pulsed electric field therapy for neurotherapeutic applications.
09:10
An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma
0 Views •
Cited by 1 •
2024
Glioblastoma is a devastating form of primary brain cancer, and laser interstitial thermal therapy is emerging as a promising alternative to conventional surgical resection for inoperable glioblastoma. This protocol describes an optimized pre-clinical mouse model that can be used to study treatment effects or adjuvant and combinatorial treatments.
FAQs
MGMT promoter methylation serves as a prognostic biomarker in glioblastoma research. Methylation analysis examines this regulatory region to help relate tumor biology to expected outcomes, while broader evaluation of DNA-repair pathways helps explain differences in response to DNA-damaging treatment. These findings can support patient stratification, interpretation of treatment results, and the design of more focused clinical trials.
Tumor heterogeneity means that genetically distinct cell populations can coexist within the same glioblastoma. A treatment that affects one population may not control others, allowing resistant cells to contribute to recurrence. Molecular profiling helps characterize this variation and can reveal why a uniform treatment strategy may produce inconsistent responses across tumors or even within different regions of one tumor.
The blood-brain barrier is an important biological constraint because it can limit how therapies reach tumor tissue in the brain. Consequently, treatment effectiveness depends not only on whether a therapy can damage tumor cells, but also on whether it can access them at a useful level. This limitation helps explain the need to investigate alternative, targeted, and emerging therapeutic approaches.
DNA-repair pathways influence how tumor cells respond to treatments that damage DNA, including temozolomide. Differences in these pathways can affect whether damaged tumor-cell DNA remains harmful or is repaired, contributing to variation in treatment response. Studying repair mechanisms alongside genetic alterations and methylation patterns therefore helps researchers identify biomarkers and refine treatment strategies.
The commonly described workflow begins with maximal safe surgical resection, followed by radiation and temozolomide. Surgery reduces the tumor burden while preserving as much function as possible, and the subsequent treatments address remaining tumor cells through complementary approaches. Genetic and methylation findings can then provide additional context for prognosis, treatment-response studies, and decisions about clinical-trial enrollment.
Researchers use molecular profiling to examine genetic alterations and other tumor characteristics, while methylation analysis evaluates patterns that help classify glioblastomas. Together, these approaches can identify prognostic biomarkers, clarify biological subgroups, and support more precise clinical-trial design. Their value extends beyond classification because they connect tumor biology with treatment response, recurrence, and emerging personalized strategies.